论文信息 - Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). - 字舞流文

Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).

Tae Won Kim | P. Ruff | M. Boedigheimer | M. Peeters | S. Tjulandin | S. Cascinu | T. Price | Jin Li | R. Sidhu | Anne L. Thomas | Kathy Zhang | S. Murugappan | K. Newhall | A. Suresh